Abstract
With the issues of climate change continuously taking center stage, there is thus a pressing need for the pharmaceutical companies to assess the sustainability of their supply chains. However, the highly regulated nature of the industry has prompted various supply chain decisions such as material sourcing, siting of plants, and distribution network configuration to be locked into the registration of the new drug. This could consequently lead to inefficient supply chain operation during the drug commercial stage, yielding high greenhouse gas emissions per unit of drug product. Previously, we have proposed a systematic framework for design of a sustainable commercial-stage pharmaceutical supply chain network that can be driven from the early drug development stages. In this paper, we extend the framework by incorporating more functionalities. We also introduce a novel decision support system, called PharmaSC, which implements the framework. PharmaSC system has been developed by integrating two computer tools—an Excel-based analytic hierarchy process and LLamasoft’s Supply Chain Guru—into one coherent framework for selecting the most suitable suppliers and manufacturers, mapping a supply chain superstructure network, and optimizing the network to identify and resolve trade-offs between economic and environmental factor. To illustrate the system, an industrially motivated case study involving a paclitaxel production is solved.
Graphical abstract
Similar content being viewed by others
References
Ahmadi HB, Kusi-Sarpong S, Rezaei J (2017) Assessing the social sustainability of supply chains using best worst method. Resour Conserv Recycl 126:99–106
Alinezad A, Seif A, Esfandiari N (2013) Supplier evaluation and selection with QFD and FAHP in a pharmaceutical company. Int J Adv Manuf Technol 68:355–364
BC Cancer Agency (2016) Paclitaxel. http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Paclitaxel_monograph_1Apr2016.pdf. Accessed 24 May 2017
Biogen (2015) Corporate citizenship report. https://www.biogen.com/content/dam/corporate/en_us/pdfs/corporate-citizenship-report/2015/BiogenCCR2015.pdf. Accessed 24 May 2017
Carver D, Prout T, Ewald H, Elliott R, Handreck P (1998) Injectable composition. US Patent 5,733,888
CDP (2017) Missing link: harnessing the power of purchasing for a sustainable future. https://www.bsr.org/reports/Report-Supply-Chain-Climate-Change-2017.pdf. Accessed 24 May 2017
CenterWatch (2017) Overview of clinical trials. http://www.centerwatch.com/clinical-trials/overview.aspx. Accessed 18 August 2017
Chatterjee B (2014) Case study: applying a risk-based decision making framework for outsourcing. Pharm Eng 34:1–6
Enyinda CI, Dunu E, Bell-Hanyes J (2010) A model for quantifying strategic supplier selection: evidence from a generic pharmaceutical firm supply chain. Int J Bus Mark Decis Sci 3(2):25–44
Gencer C, Gürpinar D (2007) Analytic network process in supplier selection: a case study in an electronic firm. Appl Math Model 31:2475–2486
GSK (2017) Annual report 2016. https://annualreport.gsk.com/assets/downloads/1_GSK.AR.FULL.V4.pdf. Accessed 24 May 2017
Hansen KRN, Grunow M (2015) Planning operations before market launch for balancing time-to-market and risks in pharmaceutical supply chains. Int J Prod Econ 161:129–139
Hughes JP, Rees S, Kalindjian SB, Philpott KL (2011) Principles of early drug discovery. Br J Pharmacol 162:1239–1249
Ishizaka A, Labib A (2009) Analytic hierarchy process and expert choice: benefits and limitations. OR Insight 22(4):201–220
Kirytopoulos K, Leopoulos V, Voulgaridou D (2008) Supplier selection in pharmaceutical industry, an analytic network process approach. Benchmark Int J 15(4):494–516
Laghrabli S, Benabbou L, Berrado A (2016) Multi-criteria aid model for transportation supplier selection: case of a pharmaceutical supply chain. In: Alaoui AEH, Benadada Y, Boukachour J (eds) 3rd international conference on logistics operations management, IEEE, Piscataway, pp 1–6
Lamasoft L (2015) Supply chain guru version 8.2. LLamasoft Inc., Ann Arbor
Lamasoft L (2017) LLamacon 2017 South East Asia. http://www2.LLamasoft.com/LLAMACON2017-SEA-July2017. Accessed 11 July 2018
Low YS, Halim I, Adhitya A, Wee C, Sharratt P (2016) Systematic framework for design of environmentally sustainable pharmaceutical supply chain network. J Pharm Innov 11:250–263
Lowell Center for Sustainable Production (1998) What is sustainable production? http://www.sustainableproduction.org/abou.what.php. Accessed 24 May 2017
Lumpkin M (1995) Guidance for industry content and format of investigational new drug applications (INDs) for phase 1 studies of drugs, including well-characterized, therapeutic, biotechnology-derived products. https://www.fda.gov/downloads/drugs/ guidancecomplianceregulatoryinformation/guidances/ucm071597.pdf. Accessed 18 Aug 2017
Mousazadeh M, Torabi SA, Zahiri B (2015) A robust possibilistic programming approach for pharmaceutical supply chain network design. Comput Chem Eng 82:115–128
Mu E, Pereyra-Rojas M (2017) Practical decision making: an introduction to the analytic hierarchy process (AHP) using super decisions V2. Springer, Cham
NHS (2015) Calculating and reporting greenhouse gas emissions for pharmaceutical products.http://www.sduhealth.org.uk/documents/publications/2015/Calculating_and_Reporting_GHG_Emisions_for_Pharmaceutical_Products_-_August_2015.pdf. Accessed 22 Aug 2017
Niziolek L, Chiam TC, Yih Y (2012) A simulation-based study of distribution strategies for pharmaceutical supply chains. IIE Trans Healthc Syst Eng 2(3):181–189
Norris SMP, Pankevich DE, Davis M, Altevogt BM (2014) Improving and accelerating therapeutic development for nervous system disorders. https://www.ncbi.nlm.nih.gov/books/NBK169736/pdf/Bookshelf_NBK169736.pdf. Accessed 17 Aug 2017
PAT Research (2018) Top 10 supply chain network design software. https://www.predictiveanalyticstoday.com/top-supply-chain-network-design-software/. Accessed 11 July 2018
Patel N, Stewart S (2007) Commercial production of anti-cancer agent paclitaxel. http://www.intelligen.com/literature.html. Accessed 24 May 2017
Pfizer (2017) 2016 annual review│accelerating patient impact. https://www.pfizer.com/files/investors/financial_reports/annual_reports/2016/assets/pdfs/pfi2016ar-full-report.pdf. Accessed 24 May 2017
Pharmaceutical Research and Manufacturers of America (2007) Drug discovery and development understanding the R&D process. http://cmidd.northwestern.edu/files/ 2015/10/Drug_RD_Brochure-12e7vs6.pdf. Accessed 18 Aug 2017
PWC (2011) Pharma 2020: supplying the future which path will you take? http://www.pwc.com/gx/en/pharma-life-sciences/pharma-2020/assets/pharma-2020-supplying-the-future.pdf. Accessed 24 May 2017
Rees H (2011) Supply chain management in the drug industry: delivering patient value for pharmaceuticals and biologics. John Wiley & Sons Inc., Hoboken
Saaty TL (1980) The analytic hierarchy process. McGraw-Hill, New York
Saaty TL, Vargas LG (1987) Uncertainty and rank order in the analytic hierarchy process. Eur J Oper Res 32:107–117
Singh RK, Kumar R, Kumar P (2016) Strategic issues in pharmaceutical supply chains: a review. Int J Pharm Healthc Mark 10(3):234–257
Sousa RT, Liu S, Papageorgiou LG, Shah N (2011) Global supply chain planning for pharmaceuticals. Chem Eng Res Des 89(11):2396–2409
Spilker B (1984) Guide to clinical trials and developing protocols. Raven Press, New York
UNEP (2016) The emissions gap report 2016—executive summary. https://uneplive.unep.org/media/docs/theme/13/egr_2016_executive_summary_en.pdf. Accessed 24 May 2017
Upfal J (2007) The australian drug guide: every person’s guide to prescription and over-the-counter medicines, street drugs, vaccines, vitamins and minerals. Black Inc., Melbourne
US Department of Health and Human Services (2003) Guidance for industry INDs for phase 2 and phase 3 studies chemistry, manufacturing, and controls information. https://www.fda.gov/downloads/Drugs/Guidances/ucm070567.pdf. Accessed 18 August 2017
Uthayakumar R, Priyan S (2013) Pharmaceutical supply chain and inventory management strategies: optimization for a pharmaceutical company and a hospital. Oper Res Health Care 2:52–64
Yadav A, Bhandari G, Ergu D, Ali M, Anis M (2015) Supplier selection by AHP in KMC pharmaceutical: use of GMIBM method for inconsistency adjustment. J Manag Res 7(5):19–46
Zahiri B, Zhuang J, Mohammadi M (2017) Toward an integrated sustainable-resilient supply chain: a pharmaceutical case study. Transp Res Part E Logist Transp Rev 103:109–142
Zahiri B, Jula P, Tavakkoli-Moghaddam R (2018) Design of a pharmaceutical supply chain network under uncertainty considering perishability and substitutability of products. Inf Sci 423:257–283
Acknowledgements
The authors would like to thank GSK-EDB Trust Fund for financial support of this project. This project has been awarded IChemE Singapore Sustainable Technology Award 2017.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
Rights and permissions
About this article
Cite this article
Halim, I., Ang, P. & Adhitya, A. A decision support framework and system for design of sustainable pharmaceutical supply chain network. Clean Techn Environ Policy 21, 431–446 (2019). https://doi.org/10.1007/s10098-018-1646-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10098-018-1646-8